1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1647
  6. Examiner Bunner

Examiner Bunner Bridget E

1647-BUNNER-BRIDGET-E

Employment Information

Art Unit:1647 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
436 — Chemistry: analytical and immunological testing
604 — Surgery
536 — Organic compounds -- part of the class 532-570 series
600 — Surgery
506 — Combinatorial chemistry technology: method, library, apparatus
Phone:(571) 272-0881
Email:bridget.bunner@uspto.gov
Location:VA 22314
Title:Pat Examnr (Biolgy)
Service:26 years
Grade:GS-14

Grant Rate and Difficulty Ranking

66
3-Year Grant rate: 66% over 310 cases
Difficulty: Harder
Difficulty Percentile: 66th

With Examiner Bunner, you have a 66% chance of getting an issued patent by 3 years after the first office action. Examiner Bunner is a harder examiner and in the 66th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Bunner, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1647

Examiner Bunner's grant rate is higher than that of Art Unit 1647 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Bunner 1.3
Art Unit 1647 1.5

Interview Benefit

Grant Rate without Interview

Examiner Bunner has granted 190 of 291 cases without any applicant-requested interviews for a grant rate of 65%.

Grant Rate with Interview

Examiner Bunner has granted 15 of 19 cases with at least one applicant-requested interview for a grant rate of 79%.

Interview Benefit

With Examiner Bunner, conducting an interview increases your chance of getting a patent granted by 22%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17710559 Hemostatic Textile Rejection information available with a Premium Stats subscription. See our pricing. Patented View
19006997 Chimeric Antigen And T Cell Receptors And Methods Of Use Patented View
17792608 Method Of Producing Adm Collagen Fiber, Adm Collagen Fiber Produced Using Method, And Apparatus For Producing Adm Collagen Fiber Patented View
18167265 Amelioration And Treatment Of Infarction Damage Abandoned View
18474781 Treatments Administering Chimeric Igg Fc Receptor Comprising An Extracellular Domain Of Cd64 Patented View
17924427 Inhibition Of Sars-Cov-2 Infection Through Syndecans Abandoned View
17415348 Combination Treatments Of Cancer Comprising A Tlr Agonist Abandoned View
17441708 Anti-Egfrviii Antibodies And Antigen-Binding Fragments Thereof Patented View
17767606 Anti-Chemokine Like Receptor 1 Humanized Antibodies And Their Therapeutic Applications Patented View
16765509 Highly Specific Zika Neutralizing Human Antibodies Patented View
18191712 Neutralizing Anti-Tl1a Monoclonal Antibodies Abandoned View
18327456 Multi-Specific Binding Proteins For Cancer Treatment Patented View
17616497 Use Of Cd9 As A Biomarker And As A Biotarget In Glomerulonephritis Or Glomerulosclerosis Patented View
18458692 Cd47 Blockade Therapy With Cd38 Antibody Abandoned View
16904319 Allogeneic T-Cell-Based Hiv Vaccine To Induce Cellular And Humoral Immunity Abandoned View
17665909 Anti-Cd40 Antibodies Abandoned View
17798481 Methods Of Use Of Soluble Cd24 For Treating Sars-Cov-2 Infection Abandoned View
17733640 Compositions And Methods For Enhancing Innate Immunity In A Subject For Treatment Of Infections And Cancer And Other Acute And Chronic Conditions Of The Eye Patented View
17796307 Methods Of Use Of Soluble Cd24 For Treating Viral Pneumonia Abandoned View
17738620 Interleukin-4 Receptor-Binding Fusion Proteins And Uses Thereof Patented View
17634120 Novel Composition Comprising Antibodies Abandoned View
17167754 Antibody Formulations Patented View
17697070 S-Layer Protein 2d Lattice Coupled Detergent-Free Gpcr Bioelectronic Interfaces, Devices, And Methods For Use Thereof Abandoned View
17832654 Methods Of Risk Assessment And Disease Classification Abandoned View
17267066 Antibodies That Bind Cd277 And Uses Thereof Patented View
16631898 Cell Atlas Of Healthy And Diseased Barrier Tissues Abandoned View
17299239 Regulatable Cell Surface Receptors And Related Compositions And Methods Patented View
17933229 Novel Anti-Pad4 Antibody Patented View
18069704 Antibody Constructs For Dll3 And Cd3 Patented View
17289201 Retinal Ganglion Cell Death Inhibitor Patented View
17694541 Compositions And Methods For Targeted Immunomodulatory Antibodies And Fusion Proteins Abandoned View
18942121 Tnf-Alpha Variant Fusion Molecules Patented View
17312590 Immunohistochemical Staining For Gsk-3 Abandoned View
17252449 Combination Of Lif Inhibitors And Platinum-Based Antineoplastic Agents For Use In Treating Cancer Abandoned View
17557654 Protease-Activating Cd45-Gate Car Patented View
18296510 Methods And Compositions For Immunomodulation Patented View
18183804 Methods And Compositions For Inducing Hematopoietic Cell Differentiation Patented View
18337875 Humanized Antibody Specific For Cd22 And Chimeric Antigen Receptor Using The Same Patented View
17423999 Anti-Elastin Antibodies And Methods Of Use Patented View
17841595 Proteolytically Cleavable Chimeric Polypeptides And Methods Of Use Thereof Patented View
17561606 Compositions Comprising Albumin-Fms-Like Tyrosine Kinase 3 Ligand Fusion Proteins And Uses Thereof Patented View
17286359 Method For Determining Glomerular Filtration Ability Patented View
17284379 Compounds And Therapeutic Uses Thereof Patented View
18107386 Prefilled Syringe With Pegfilgrastim Having Optimized Dose And Methods Related Thereto Patented View
17816823 Il-2 Superagonists In Combination With Anti-Pd-1 Antibodies Patented View
17450282 Anti-Notch3 Antibody Patented View
17427581 Half-Life Extended Immtac Binding Cd3 And A Hla-A*02 Restricted Peptide Abandoned View
18185443 Vegfr Fusion Protein Pharmaceutical Composition Patented View
18321249 Anti-Jagged Antibodies And Methods Of Use Abandoned View
17236467 Antibody Constructs For Dll3 And Cd3 Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.